tiprankstipranks
Advertisement
Advertisement

Twilio, Netflix, Dow, MELI, ARM Trending With Analysts

Twilio, Netflix, Dow, MELI, ARM Trending With Analysts

Analysts are intrested in these 5 stocks: ( (TWLO) ), ( (NFLX) ), ( (DOW) ), ( (MELI) ) and ( (ARM) ). Here is a breakdown of their recent ratings and the rationale behind them.

Claim 30% Off TipRanks

Twilio is back in the spotlight as Jefferies’ Samad Samana upgrades the stock to Buy, arguing the company is set to become a key layer in the fast-emerging Voice AI ecosystem. By moving “up the stack” with products like ConversationRelay, Twilio can bundle media streaming, speech-to-text and orchestration to capture far more revenue per call than in traditional telephony.

The analyst sees Voice AI adoption as a structural growth driver, with even modest enterprise uptake potentially lifting gross margins and free cash flow for years. With a $160 price target implying higher valuation multiples on 2027 estimates, the call suggests current prices may underappreciate Twilio’s role in an agentic AI world and the premium it can charge for AI-enabled communications.

Netflix also earns an upgrade to Buy from Eric Sheridan, who highlights improving momentum across pricing, the ad-supported tier and potential capital returns. Heading into Q1 2026 results, he points to three pillars of the bull case: steady revenue growth from paid subscribers plus higher revenue per member, operating leverage from disciplined costs, and stronger free cash flow.

The analyst lifts his price target from $100 to $120, arguing that the balance of risk and reward has turned more attractive from current levels. For investors, the message is that Netflix may still have room to grow earnings and shareholder payouts, even as the streaming landscape matures and competition remains intense.

Dow Inc. faces a more cautious view, with Matthew Deyoe at BofA downgrading the stock to Underperform and setting a $35 price objective. After a 71% year-to-date rally, he believes the share price is now capitalizing earnings boosted by temporary factors linked to the Iran conflict and tight petrochemical markets, rather than sustainable fundamentals.

While he does see strong margin expansion for Dow in 2026 as North American and European assets benefit from dislocations, he expects petrochemical prices and profits to ease from a 2Q26 peak into 2027. His valuation now applies a lower EBITDA multiple than the five-year average, reflecting concern that as markets normalize, investors may refocus on more modest long-term earnings.

MercadoLibre gets a vote of confidence as Jefferies upgrades the Latin American e-commerce and fintech leader to Buy with a $2,600 price target. The team argues that ongoing investment in free shipping, marketing and credit has compressed margins and driven earnings downgrades, but is also powering much stronger revenue growth and long-term operating leverage.

They note that MELI now trades at historically low valuation multiples despite massive growth in revenue, payments volume and logistics since 2020. Competition in Brazilian e-commerce remains a hot topic, yet recent fee hikes and the absence of any slowdown in MELI’s user or volume growth support the view that the company’s growth engine is intact and that current pricing may not reflect its potential.

Arm Holdings, by contrast, is seeing expectations tempered as Morgan Stanley’s Lee Simpson moves the stock to an Equal-weight (Hold) rating with a $150 fair value. The firm praises Arm’s strategic shift into chip making, particularly AGI-oriented CPU designs tailored for agentic AI workloads, which demonstrates that power-efficient CPUs remain central in a world dominated by GPUs.

However, the report stresses that the commercial ramp of this new strategy will take time, and near-term headwinds such as end-market softness, DRAM-related issues, margin pressure and possible conflicts with licensees could cap earnings momentum and valuation. While a bullish scenario could see considerable upside if these risks fade, the base case suggests investors should be patient and treat Arm as a longer-term story rather than a near-term earnings play.

Disclaimer & DisclosureReport an Issue

1